Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28978518 | 0.83 | NPSR1 (0.33) | CYP3A4SMN1; SMN2HTTSMYD2 | |
| SCHEMBL17511798 | 0.83 | CYP3A4 (0.30) | CYP3A4SMN1; SMN2HTTSMYD2 | |
| SCHEMBL20954476 | 0.80 | TAAR1 (0.34) | TAAR1SLC6A2MAPK1 | |
| SCHEMBL707572 | 0.79 | MAPK1 (0.34) | CYP3A4SMN1; SMN2HTTSMYD2MAPK1 | |
| SCHEMBL28387134 | 0.78 | TAAR1 (0.38) | TAAR1CYP3A4CYP1A2CYP2D6PRMT1 | |
| SCHEMBL14841365 | 0.77 | TAAR1 (0.37) | TAAR1CYP3A4CYP1A2CYP2D6PRMT1 | |
| SCHEMBL453430 | 0.76 | SMN1; SMN2 (0.44) | TAAR1CYP3A4CYP1A2SMN1; SMN2HTT | |
| SCHEMBL4835281 | 0.75 | MAPK1 (0.34) | TAAR1CYP3A4SMN1; SMN2SLC6A2HTT | |
| SCHEMBL15888456 | 0.74 | MAPK1 (0.37) | TAAR1CYP3A4SMN1; SMN2SLC6A2HTT | |
| SCHEMBL79874 | 0.74 | MAPK1 (0.37) | TAAR1CYP3A4SMN1; SMN2SLC6A2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | UCB Biopharma SRL (BE) | 2026-03-17 | — | — | US | disclosed |
| WO-2024026424-A1 | QUINAZOLINONE DERIVATIVES AS AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230303517-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230303517-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (GB) | 2023-09-28 | — | — | US | disclosed |
| CN-114845778-A | Dihydrocyclopentaisoquinoline sulfonamide derivative compound | UCB生物制药有限责任公司 | 2022-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303517-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | FCER2, FCGR1A, FCGR2A | TAAR1 1907/4885CYP3A4 1057/4885CYP1A2 808/4885 |
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | FCGR2A, FCER2, FCGR1A | TAAR1 769/4885CYP3A4 1069/4885CYP1A2 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.